Result of AGM
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
London, UK, 20 June 2024: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia), announces the voting results for each resolution set out in the Notice of Annual General Meeting 2024. The Board reports that all resolutions were passed: 1 to 10 passed as ordinary resolutions and 11 to 12 passed as special resolutions.
The following table shows the votes cast on each resolution:
| VOTES FOR | % | VOTES AGAINST | % | WITHHELD VOTES | |
|---|---|---|---|---|---|
| Resolution 1 | 371,135,672 | 99.65% | 1,321,765 | 0.35% | 387,002 |
| Resolution 2 | 367,256,140 | 98.70% | 4,821,667 | 1.30% | 766,632 |
| Resolution 3 | 368,781,407 | 99.11% | 3,296,400 | 0.89% | 766,632 |
| Resolution 4 | 368,781,161 | 99.11% | 3,296,646 | 0.89% | 766,632 |
| Resolution 5 | 369,852,377 | 99.40% | 2,225,430 | 0.60% | 766,632 |
| Resolution 6 | 369,852,377 | 99.39% | 2,266,765 | 0.61% | 725,297 |
| Resolution 7 | 368,193,486 | 98.96% | 3,884,321 | 1.04% | 766,632 |
| Resolution 8 | 371,077,210 | 99.63% | 1,380,227 | 0.37% | 387,002 |
| Resolution 9 | 370,260,710 | 99.38% | 2,293,669 | 0.62% | 290,060 |
| Resolution 10 | 368,304,167 | 98.90% | 4,079,150 | 1.10% | 461,122 |
| Resolution 11 | 368,067,995 | 98.84% | 4,305,730 | 1.16% | 470,714 |
| Resolution 12 | 367,071,290 | 98.53% | 5,470,921 | 1.47% | 302,228 |
Notes:
- Number of shares in issue 782,056,367.
- Details of the votes received on the resolutions are available on the Company's website:
- Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anaemia (IDA) affect about 20 million people in the U.S. and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer® has the potential to meet an important unmet medical need for both physicians and patients.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.